sarcoidosi
system
diseas
character
noncas
granulomat
inflamm
tremend
clinic
heterogen
uncertain
pathobiolog
lack
clinic
use
biomark
genom
research
antitrypsin
defici
sarcoidosi
grad
studi
observ
cohort
studi
design
explor
role
lung
microbiom
genom
two
diseas
articl
describ
design
rational
grad
studi
sarcoidosi
protocol
studi
address
hypothesi
distinct
pattern
lung
microbiom
characterist
sarcoidosi
phenotyp
reflect
chang
system
inflammatori
respons
measur
peripher
blood
chang
gene
transcript
goal
enrol
particip
minimum
clinic
phenotyp
subgroup
priorit
clinic
relev
understand
pathobiolog
clinic
heterogen
sarcoidosi
particip
confirm
diagnosi
sarcoidosi
undergo
baselin
visit
selfadminist
questionnair
chest
comput
tomographi
pulmonari
function
test
blood
urin
test
research
clinic
bronchoscopi
research
bronchoalveolar
lavag
perform
obtain
sampl
genom
microbiom
analys
comparison
made
blood
genom
analysi
clinic
phenotyp
variabl
followup
visit
plan
assess
particip
clinic
cours
use
integr
approach
analysi
microbiom
genom
select
clinic
phenotyp
grad
studi
power
posit
inform
direct
studi
pathobiolog
sarcoidosi
identifi
diagnost
prognost
biomark
provid
novel
molecular
phenotyp
could
lead
improv
person
approach
therapi
sarcoidosi
sarcoidosi
multisystem
inflammatori
diseas
character
noncas
granuloma
site
inflamm
lung
intrathorac
lymph
node
involv
case
variabl
involv
organ
tissu
tremend
heterogen
sarcoidosi
clinic
manifest
sever
clinic
cours
vari
among
differ
ethnic
racial
group
despit
progress
understand
genet
immunolog
basi
sarcoidosi
determin
diseas
manifest
clinic
cours
remain
unclear
etiolog
current
valid
biomark
provid
global
organ
assess
predict
diseas
cours
respons
therapi
human
microbiom
critic
determin
health
diseas
lung
microbiom
like
critic
role
pathobiolog
immunolog
lung
diseas
sarcoidosi
nation
heart
lung
blood
institut
solicit
applic
genom
research
antitrypsin
defici
sarcoidosi
grad
studi
multicent
studi
involv
collabor
effort
genom
informat
center
gic
seven
clinic
center
purpos
articl
describ
design
rational
sarcoidosi
protocol
grad
studi
protocol
deriv
sarcoidosi
protocol
develop
committe
initi
hypothesi
gic
distinct
pattern
lung
microbiom
characterist
sarcoidosi
phenotyp
reflect
chang
system
inflammatori
respons
measur
peripher
blood
chang
gene
transcript
clinic
manifest
diseas
cours
sarcoidosi
variabl
larg
unpredict
repres
challeng
patient
clinician
manifest
rang
patient
acut
sarcoidosi
syndrom
chronic
sever
diseas
includ
advanc
lung
diseas
pulmonari
hypertens
cardiomyopathi
major
patient
experi
remiss
typic
within
first
year
howev
patient
unremit
chronic
diseas
lead
signific
organ
dysfunct
requir
longterm
corticosteroid
immunosuppress
therapi
mortal
may
reach
among
advanc
diseas
tradit
method
character
sarcoidosi
lung
diseas
use
chest
radiographbas
classif
scheme
refer
scad
stage
stage
system
tabl
epidemiolog
evid
scad
stage
offer
predict
valu
estim
likelihood
spontan
remiss
high
scad
stage
low
scad
stage
iii
iv
unfortun
evid
stage
system
biomark
accur
predict
diseas
cours
lack
patholog
hallmark
sarcoidosi
epithelioid
granuloma
consist
mainli
monocyt
macrophag
epithelioid
multinucl
giant
cell
lymphocyt
highlight
central
featur
pathobiolog
sarcoidosi
find
current
lack
consensu
summar
tabl
lung
sarcoidosi
inflammatori
cascad
display
polar
helper
type
lymphocyt
respons
increas
product
ifng
chemotact
proinflammatori
effector
regulatori
cytokin
signal
lead
recruit
addit
monocyt
lymphocyt
lung
macrophag
differenti
epithelioid
multinucl
giant
cell
eventu
granuloma
format
recent
studi
suggest
effector
tcell
respons
may
contribut
sarcoidosi
pathobiolog
whether
respons
critic
diseas
pathogenesi
play
role
shape
clinic
phenotyp
remain
uncertain
genet
suscept
environment
trigger
thought
caus
sarcoidosi
independ
molecular
immunolog
investig
suggest
associ
pathogen
mycobacteria
case
sarcoidosi
grad
studi
investig
contribut
molecular
evid
mycobacteri
rna
dna
protein
sarcoidosi
tissu
found
control
nonsarcoidosi
tissu
sever
research
group
report
enhanc
immun
respons
specif
mycobacteri
protein
subject
sarcoidosi
compar
control
subject
sever
studi
show
signific
overlap
transcriptom
patient
sarcoidosi
patient
tuberculosi
japanes
investig
report
strong
linkag
propionibacteria
sarcoidosi
among
japanes
subject
howev
consensu
role
microbi
infect
sarcoidosi
wherea
research
group
promot
idea
chronic
sarcoidosi
result
activ
replic
mycobacteri
propionibacteri
infect
may
respond
antimicrobi
therapi
other
posit
sarcoidosi
result
hyperimmun
respons
tissu
antigen
includ
remnant
microbi
antigen
involv
activ
ongo
infect
latter
possibl
may
associ
aberr
innat
respons
involv
aggreg
serum
amyloid
within
granuloma
studi
highlight
potenti
import
interact
lung
microbiom
genom
regul
determin
clinic
phenotyp
cours
sarcoidosi
area
focu
grad
studi
recent
studi
research
use
genomewid
transcriptom
profil
better
defin
sarcoidosi
pathogenesi
studi
confirm
associ
gene
pathway
known
relev
sarcoidosi
includ
tcell
receptor
pathway
cell
signal
prolifer
cytokin
gene
includ
ifng
grad
studi
investig
evalu
peripher
blood
gene
express
sarcoidosi
found
pattern
gene
express
associ
diseas
sever
diseas
cours
togeth
studi
support
promis
grad
studi
discov
new
molecular
signatur
defin
sarcoidosi
phenotyp
outcom
human
microbiom
microbiom
refer
set
microbi
agent
gene
contain
environ
term
metagenom
refer
analysi
genet
materi
recov
directli
environ
standard
microbiolog
virolog
method
detect
small
proport
bacteria
virus
present
variou
bodi
site
great
major
organ
uncharacter
uncultiv
thu
practic
microbiom
studi
reli
use
metagenom
approachesthat
sequencebas
rather
culturebas
approachesto
investig
microbi
commun
microbiom
studi
may
focu
fulli
enumer
microbi
agent
bodi
habitat
use
sequenc
tag
share
organ
within
group
ribosom
rrna
gene
share
bacteria
archaea
defin
gene
within
commun
shotgun
metagenom
sequenc
genet
materi
present
metagenom
provid
insight
complex
composit
microbiom
sever
bodi
site
inform
allow
us
draw
tent
conclus
relationship
specif
microbiom
health
understand
overlap
degre
commun
microbiom
nich
rudimentari
best
perhap
extens
studi
human
microbiom
human
gut
microbiom
interact
gut
microflora
independ
interact
genet
makeup
host
play
role
obes
crohn
diseas
ulcer
coliti
contrast
extens
literatur
gut
much
less
known
composit
microbi
popul
lower
respiratori
tract
health
diseas
like
undetect
organ
well
complex
relationship
multipl
pathogen
seen
patient
chronic
lung
diseas
although
healthi
lung
tradit
thought
steril
emerg
data
suggest
microbi
dna
present
healthi
lung
close
resembl
oropharynx
markedli
lesser
amount
perhap
result
microaspir
occur
even
healthi
individu
research
also
detect
presenc
uniqu
organ
tropheryma
whipplei
agent
whippl
diseas
lung
healthi
peopl
studi
lung
microbiom
challeng
given
difficulti
distinguish
true
resid
lung
versu
organ
carri
mouth
bronchoscop
well
difficulti
environment
contamin
given
low
biomass
bronchoalveolar
lavag
bal
sampl
recent
studi
support
emerg
concept
lung
microbiom
alter
lung
diseas
chronic
obstruct
pulmonari
diseas
asthma
cystic
fibrosi
littl
known
microbiom
lung
diseas
sarcoidosi
presenc
chronic
granulomat
inflammatori
respons
lung
sarcoidosi
long
suggest
infecti
agent
import
sarcoidosi
date
howev
culturebas
studi
directli
proven
infecti
pathogenesi
diseas
contrast
limit
tradit
microbi
cultur
cultureindepend
techniqu
capac
enhanc
understand
ident
complex
microbi
commun
within
lung
patient
sarcoidosi
use
unbias
sequenc
sarcoidosi
examin
one
studi
investig
studi
find
dramat
chang
lung
microbiom
examin
seven
patient
sarcoidosi
larger
studi
encompass
multipl
phenotyp
sarcoidosi
need
determin
role
microbiom
diseas
indic
publish
studi
suggest
lung
microbiom
genom
network
interact
like
play
critic
role
diseas
pathogenesi
determin
clinic
phenotyp
sarcoidosi
howev
current
state
knowledg
area
rudimentari
goal
grad
studi
perform
comprehens
analysi
microbiom
genom
pattern
interact
welldefin
sarcoidosi
phenotyp
among
question
address
follow
lung
microbiom
contribut
phenotyp
landscap
critic
interact
lung
microbiom
host
immun
respons
network
contribut
clinic
phenotyp
particularli
clinic
outcom
genom
microbiom
signatur
associ
clinic
phenotyp
outcom
begin
answer
question
studi
investig
outlin
follow
aim
identifi
peripher
blood
mononuclear
cell
pbmc
gene
express
pattern
character
distinct
sarcoidosi
phenotyp
determin
whether
pattern
lung
microbiom
associ
sarcoidosi
sever
diseas
phenotyp
correl
mrna
microrna
express
pattern
sarcoidosisaffect
organ
chang
microbiom
clinic
paramet
pbmc
gene
express
pattern
integr
clinic
transcriptom
microbiom
data
identifi
novel
molecular
phenotyp
sarcoidosi
aim
grad
studi
understand
genom
microbiom
relationship
associ
clinic
phenotyp
necessari
defin
specif
phenotyp
import
studi
manifest
could
includ
owe
diseas
heterogen
limit
sampl
size
studi
sarcoidosi
protocol
develop
committe
priorit
nine
phenotyp
tabl
basi
consider
describ
paragraph
follow
first
patient
sarcoidosi
involv
lung
wellstudi
site
diseas
pathogenesi
immun
activ
thu
patient
manifest
domin
group
second
perhap
critic
phenotyp
distinct
biolog
import
separ
remit
versu
chronic
sarcoidosi
latter
disproportion
diseas
impact
given
limit
studi
preclud
lengthi
followup
period
suffici
confid
determin
chronic
versu
remit
outcom
phenotyp
known
outcom
expect
chosen
pulmonari
sarcoidosi
chose
distinguish
pulmonari
phenotyp
basi
scad
chest
radiograph
stage
system
differ
stage
associ
differ
outcom
tabl
theoriz
prognost
inform
reflect
chang
pathobiolog
process
underli
differ
radiograph
stage
third
advanc
lung
diseas
pulmonari
fibrosi
cardiac
sarcoidosi
repres
phenotyp
portend
highest
mortal
associ
sarcoidosi
thu
deserv
specif
attent
fourth
effect
treatment
judg
critic
interpret
genom
microbiom
data
limit
phenotyp
group
sarcoidosi
readili
appar
instrument
definit
use
defin
organ
involv
thu
phenotyp
base
previous
publish
studi
valid
larg
clinic
trial
see
onlin
supplement
part
due
fact
instrument
definit
remain
move
target
advanc
imag
continu
improv
sensit
detect
inflammatori
site
sarcoidosi
howev
imag
chang
proven
clinic
function
phenotyp
signific
exampl
prognos
associ
scad
chest
radiograph
stage
system
first
use
intern
convent
valid
multipl
intern
studi
subsequ
decad
similar
scope
studi
chest
comput
tomographi
ct
correl
use
prognost
stage
despit
drawback
select
follow
nine
phenotyp
base
data
prior
publish
clinic
studi
case
control
etiolog
studi
sarcoidosi
access
clinician
experi
phenotyp
multiorgan
sarcoidosi
patient
sarcoidosi
clinic
signific
inflamm
mani
organ
may
repres
one
purest
phenotyp
term
outcom
invari
chronic
unremit
diseas
patient
widespread
inflammatori
chang
often
presenc
abdomin
sarcoidosi
typic
liver
spleen
bone
bone
marrow
involv
subdiaphragmat
lymphadenopathi
along
pulmonari
extrapulmonari
organ
involv
although
number
organ
defin
phenotyp
vari
instrument
definit
use
intent
defin
group
high
likelihood
repres
chronic
sarcoidosi
end
settl
five
organ
meet
criteria
phenotyp
base
clinic
experi
specif
data
phenotyp
stage
pulmonari
sarcoidosi
untreat
fundament
phenotyp
repres
group
activ
sarcoidosi
base
intrathorac
lymph
node
granulomat
inflamm
conduct
observ
cohort
studi
explor
role
microbiom
genom
regul
relat
specif
sarcoidosi
clinic
phenotyp
studi
design
casecontrol
studi
studi
microbiom
sarcoidosi
etiolog
achiev
goal
studi
clinic
center
recruit
subject
meet
initi
entri
criteria
detail
tabl
includ
american
thorac
societyeuropean
respiratori
societi
criteria
diagnosi
sarcoidosi
particip
either
classifi
within
target
clinic
phenotyp
defin
within
protocol
upon
review
clinic
inform
gather
initi
studi
visit
exclud
addit
studi
particip
elig
particip
undergo
selfadminist
questionnair
physic
examin
research
chest
ct
examin
pulmonari
function
test
blood
urin
test
tabl
subject
either
undergo
research
bal
part
otherwis
clinic
indic
bronchoscopi
suspect
pulmonari
sarcoidosi
recruit
undergo
researchonli
bronchoscopi
bal
former
group
diagnosi
sarcoidosi
confirm
biopsi
patient
enter
databas
particip
undergo
full
test
sampl
collect
altern
diagnosi
made
recruit
undergo
test
particip
elect
undergo
bronchial
brush
appropri
skin
biopsi
suspect
sarcoidosi
skin
lesion
subject
cardiac
phenotyp
group
subset
stage
iv
pulmonari
sarcoidosi
particip
undergo
bronchoscopi
owe
higher
theoret
risk
bronchoscop
complic
rational
collect
bal
bronchial
brush
blood
sampl
clear
highthroughput
unbias
analys
lung
microbiom
potenti
identifi
pattern
lung
microbiom
determin
diseas
activ
persist
well
respons
therapi
sampl
bal
bronchial
brush
oral
wash
offer
opportun
compar
region
lung
microbiom
environ
alveolar
compart
proxim
bronchial
wall
oral
environ
focus
access
blood
cell
genom
analys
enabl
grad
studi
research
identifi
marker
diseas
phenotyp
sever
outcom
easili
transfer
clinic
arena
addit
studi
may
indic
whether
blood
sampl
surrog
bal
sampl
analysi
analysi
transcriptom
sarcoidosi
tissu
bal
cell
peripher
blood
microbiom
bal
fluid
biochem
signatur
bal
serum
plasma
urin
provid
opportun
identifi
new
molecular
phenotyp
correl
diseas
phenotyp
organ
system
involv
achiev
aim
studi
plan
recruit
goal
particip
least
questionnair
selfadminist
questionnair
collect
assess
dyspnea
fatigu
qualiti
life
use
publish
instrument
tabl
onlin
supplement
inform
person
medic
risk
factor
includ
demograph
variabl
current
past
medic
histori
reflux
histori
current
past
medic
use
obtain
detail
inform
occup
recreat
environment
residenti
exposur
assess
use
modif
access
occup
environment
questionnair
variabl
correl
phenotypespecif
associ
microbiom
genom
express
pattern
pulmonari
manifest
sarcoidosi
variabl
differ
subgroup
demonstr
domin
restrict
obstruct
reduc
diffus
capac
impair
mixtur
physiolog
impair
preand
postbronchodil
spirometri
perform
assess
degre
bronchodil
respons
systemat
studi
sarcoidosi
confirm
restrict
ventilatori
impair
diagnosi
sarcoidosi
establish
consensu
criteria
atser
confirm
either
biopsi
manifest
consist
acut
sarcoidosi
syndrom
absenc
known
diagnosi
b
suspect
diagnosi
sarcoidosi
schedul
undergo
biopsi
procedur
confirm
diagnosi
sarcoidosi
use
consensu
criteria
atser
abl
toler
will
undergo
studi
procedur
capabl
understand
studi
form
provid
sign
inform
consent
exclus
criteria
histori
comorbid
condit
sever
enough
significantli
increas
risk
base
investig
discret
current
activ
smoker
undergo
bronchoscopi
clinic
research
one
follow
sever
pulmonari
impair
predict
fvc
l
fev
dl
co
predict
rest
hypoxemia
without
supplement
oxygen
b
comorbid
diseas
would
preclud
bronchoscopi
c
hypersensit
intoler
drug
requir
sedat
consciou
sedat
bronchoscopi
known
system
autoimmun
diseas
rheumatoid
arthriti
lupu
scleroderma
syndrom
found
altern
interstiti
lung
diseas
evalu
andor
screen
diagnosi
unstabl
cardiovascular
diseas
includ
myocardi
infarct
past
wk
uncontrol
congest
heart
failur
uncontrol
arrhythmia
use
anticoagul
patient
take
warfarin
clopidogrel
exclud
patient
aspirin
alon
studi
even
concurr
use
dementia
cognit
dysfunct
opinion
investig
would
prevent
particip
consent
complet
studi
procedur
nonsarcoidosi
pulmonari
diseas
eg
rheumatoid
arthriti
lupu
scleroderma
opinion
investig
limit
interpret
analysi
sarcoidosi
pulmonari
diseas
primari
biliari
cirrhosi
autoimmun
hepat
crohn
diseas
chronic
beryllium
diseas
activ
bacteri
viral
infect
time
screen
activ
ongo
seriou
infect
includ
hiv
hbv
hcv
activ
tuberculosi
take
medic
tuberculosi
histori
demyelin
diseas
lymphoprolif
diseas
malign
presum
cure
nonmetastat
skin
cancer
evid
like
malign
chest
xray
current
pregnant
time
screen
current
institution
eg
prison
longterm
care
facil
hypersensit
intoler
albuterol
sulfat
propel
excipi
inhal
histori
lung
volum
reduct
surgeri
lung
resect
bronchoscop
lung
volum
reduct
form
histori
lung
organ
transplant
unabl
comprehend
consent
document
andor
questionnair
condit
exclus
particip
present
upper
respiratori
infect
pulmonari
exacerb
either
sole
particip
identifi
clinic
treat
preced
wk
rescreen
studi
window
close
particip
present
current
use
acut
antibiot
taken
acut
antibiot
within
preced
wk
rescreen
studi
discontinu
acut
antibiot
femal
particip
present
mo
give
birth
ask
reschedul
visit
mo
pass
sinc
birth
former
smoker
quit
mo
enrol
lung
volum
obtain
particip
whose
slow
vital
capac
less
predict
valu
american
thorac
societyeuropean
respiratori
societi
guidelin
serv
primari
guidanc
conduct
interpret
spirometr
lung
volum
measur
measur
singlebreath
carbon
monoxid
diffus
capac
radiolog
studi
includ
standard
chest
radiograph
classifi
particip
accord
scad
stage
system
research
chest
ct
scan
chest
ct
protocol
develop
account
potenti
scanner
variat
across
clinic
center
bodi
habitu
tabl
onlin
supplement
helic
spiral
chest
ct
data
acquir
particip
supin
posit
breath
hold
end
inspir
total
lung
capac
without
radiopaqu
contrast
dye
radiat
exposur
base
three
bodi
mass
index
categori
recruit
potenti
studi
particip
either
establish
diagnosi
sarcoidosi
highli
suspect
sarcoidosi
recruit
clinic
center
flyer
websit
mail
physician
referr
determin
elig
studi
particip
base
inclus
exclus
criteria
list
tabl
elig
particip
confirm
sarcoidosi
diagnosi
approach
request
consent
undergo
studi
procedur
use
one
three
consent
form
depend
whether
research
bronchoscopi
clinic
bronchoscopi
bronchoscopi
plan
recruit
consent
procedur
compliant
current
health
insur
portabl
account
act
regul
approv
local
institut
review
board
irb
well
irb
gic
phenotyp
base
categori
note
determin
use
modifi
organ
assess
instrument
initi
develop
access
studi
elig
particip
without
confirm
clinic
diagnosi
consent
clinic
bronchoscopi
diagnosi
confirm
tissu
biopsi
particip
enrol
studi
databas
complet
test
particip
ask
consent
skin
biopsi
cutan
involv
deem
consist
sarcoidosi
biopsi
plan
clinic
purpos
bronchoscopi
perform
goal
minim
bia
collect
sampl
microbiom
analysi
previous
describ
grad
studi
investig
briefli
anesthesia
induc
bronchoscopi
preced
tongu
scrape
oral
rins
collect
microbi
commun
tongu
oral
mouth
upper
airway
particip
ask
gargl
antisept
wash
oral
decontamin
sampl
work
channel
bronchoscop
also
collect
assess
preexist
level
microbi
contamin
bal
perform
use
predesign
algorithm
guid
radiograph
site
involv
chest
radiograph
ct
scan
preferenti
locat
right
middl
lobe
lingula
particip
agre
undergo
bronchial
brush
procedur
perform
follow
bal
sampl
collect
studi
detail
tabl
bronchoscop
sampl
process
maxim
sampl
integr
rna
microrna
dna
protein
recent
describ
portion
bal
fluid
centrifug
separ
cellfre
bal
fluid
supernat
bal
cell
pellet
microbiom
transcriptom
biochem
analys
subject
undergo
clinic
bronchoscopi
portion
bal
sampl
sent
routin
clinic
test
discret
bronchoscopist
remaind
collect
research
purpos
bronchial
brush
place
solut
preserv
rna
integr
blood
collect
phlebotomi
aliquot
sent
clinic
laboratori
test
typic
obtain
assess
patient
sarcoidosi
patient
tabl
pbmc
separ
use
singletub
separ
system
serum
plasma
store
frozen
aliquot
whole
blood
place
solut
design
preserv
rna
dna
integr
urin
sampl
obtain
assay
cotinin
clinic
site
object
test
recent
smoke
stool
sampl
request
particip
undergo
research
bal
collect
futur
gut
microbiom
comparison
lung
microbiom
sampl
ship
gic
store
biorepositori
data
enter
clinic
site
use
encrypt
password
protect
webbas
system
clinicianr
data
enter
system
paper
form
participantr
data
enter
directli
system
via
tablet
comput
radiograph
data
transfer
electron
gic
deidentifi
format
compliant
digit
imag
commun
medicin
standard
data
share
import
featur
grad
studi
gic
develop
webbas
data
portal
provid
dynam
exploratori
cohort
select
tool
allow
data
explor
across
larg
number
clinic
variabl
microbiom
genom
data
deposit
appropri
nation
center
biotechnolog
inform
repositori
databas
genotyp
phenotyp
known
dbgap
accord
nation
institut
health
polici
identif
bacteri
speci
within
environ
amplif
rrna
gene
rdna
use
genet
locu
present
bacteri
speci
polymeras
chain
reaction
primer
target
conserv
region
gene
share
bacteria
flank
hypervari
region
differ
nine
hypervari
region
rdna
use
bacteri
speci
identif
region
better
discriminatori
valu
other
contrast
conserv
gene
target
identif
virus
thu
whole
shotgun
sequenc
sampl
enrich
virus
filter
lead
effect
character
viral
commun
grad
studi
research
perform
bacteri
viral
analys
oral
wash
bal
sampl
environment
control
sampl
determin
differ
microbi
commun
structur
relat
sarcoidosi
phenotyp
clinic
cours
studi
incorpor
host
gene
express
microbiom
data
determin
interact
occur
host
organ
integr
clinic
transcriptom
microbiom
data
grad
studi
posit
identifi
novel
molecular
phenotyp
well
genom
correl
known
clinic
phenotyp
form
basi
molecular
fingerprint
predict
diseas
sever
respons
therapi
well
patient
stratif
clinic
trial
normal
gene
express
level
relat
establish
phenotyp
crossphenotyp
characterist
use
linear
model
ie
analysi
varianc
linear
regress
tool
sampl
size
calcul
analysi
varianc
base
prior
data
show
minimum
sampl
per
group
requir
detect
power
exceed
chang
allow
singl
fals
posit
assum
gene
truli
differenti
express
thu
overal
sampl
size
particip
goal
subject
per
phenotyp
plan
allow
incomplet
data
collect
fundament
grad
studi
studi
interact
integr
stateoftheart
highthroughput
microbiom
genom
analys
welldefin
clinic
phenotyp
measur
qualiti
life
environment
variabl
diseas
tremend
unexplain
clinic
heterogen
inform
like
provid
wealth
inform
potenti
mechanist
pathway
interact
play
critic
role
diseas
pathogenesi
determin
clinic
manifest
clinic
cours
respons
therapi
futur
studi
base
data
foundat
provid
grad
studi
might
includ
multipl
potenti
avenu
investig
shown
tabl
grad
studi
multicent
collabor
task
investig
role
lung
microbiom
systemwid
genom
express
two
orphan
tabl
grad
studi
foundat
futur
studi
sarcoidosi
associ
microbiom
genom
signatur
clinic
phenotyp
provid
focus
mechanist
studi
diseas
pathobiolog
genom
analys
lung
epitheli
brush
blood
direct
studi
local
system
inflammatori
pathway
lung
extrapulmonari
diseas
valid
novel
previous
discov
genom
biomark
discoveri
molecular
phenotyp
inform
person
therapi
base
relev
pathway
molecular
signatur
remit
vs
chronic
sarcoidosi
direct
studi
manipul
relev
pathway
microflora
diseas
cure
clinic
studi
design
diseas
antitrypsin
defici
sarcoidosi
sarcoidosi
protocol
design
explor
lung
microbiom
peripher
lung
genom
may
shape
differ
clinic
phenotyp
outcom
sarcoidosi
diseas
tremend
clinic
heterogen
uncertain
pathobiolog
lack
clinic
use
biomark
grad
studi
research
spearhead
singular
effort
integr
microbiom
genom
analys
rigor
clinic
phenotyp
suffici
scope
inform
direct
futur
studi
pathobiolog
manag
sarcoidosi
forese
futur
n
author
disclosur
avail
text
articl
wwwatsjournalsorg
acknowledg
grad
studi
investig
thank
individu
particip
studi
time
fortitud
studi
complet
also
acknowledg
program
offic
support
staff
nation
heart
lung
blood
institut
nhlbi
guidanc
studi
design
complet
grad
sarcoidosi
studi
investig
collabor
list
